[Interleukin-21 surface-modified MB49 cell vaccine for treatment of metastatic bladder in mice].
OBJECTIVE
To develop a novel vaccine by immobilizing interleukin-21 (IL-21) on the surface of MB49 cells and evaluate its effect in inducing specific cytotoxic T lymphocytes (CTLs) and antitumor immunity in a mouse model of subcutaneous metastatic bladder cancer.


METHODS
SA-IL-21 was immobilized on the surface of 30% ethanol-fixed MB49 cells to prepare the cell vaccine. C57BL/6 mice with subcutaneous implantation of MB49 bladder cancer cells were randomized into 5 groups to receive treatments with IL-21/MB49 vaccine, soluble IL-21, GFP surface-modified MB49 cells, ethanol-fixed MB49 cells, or PBS. The tumor growth and CTL were examined to assess the antitumor efficacy of the vaccine.


RESULTS
IL-21 surface-modified MB49 cell vaccine significantly inhibited the tumor growth and generated a long-lasting memory response (P<0.05). At the same effector-target (E:T) ratio, the specific CTLs induced by IL-21/MB49 vaccine showed the most potent cytotoxicity against MB49 cells (P<0.05).


CONCLUSIONS
With the protein-anchor technique, IL-21 can be efficiently immobilized on the surface of MB49 cells to prepare IL-21/MB49 cells vaccine. The novel vaccine can maintain its biological activity and significantly enhance the cytotoxicity of CTLs against bladder cancer cells.
Department of Urinary Surgery, Southern Medical University, Guangzhou, China. pjmap@126.com
Junming
J
Peng
Xiaojun
X
Shi
Dingnan
D
Chen
Zhongkun
Z
Liang
Kaijian
K
Lan
Jimin
J
Gao
Wanlong
W
Tan
D020816:Amino Acid Motifs; D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D005260:Female; D007167:Immunotherapy; D007378:Interleukins / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D000098546:Interleukin-21
D019496:Cancer Vaccines; D007378:Interleukins; D000098546:Interleukin-21